-+ 0.00%
-+ 0.00%
-+ 0.00%

MiNK Therapeutics Highlights iNKT Cell Therapy Potential In Peer-Reviewed Article Titled "CAR-iNKT Cells: Redefining The Frontiers Of Cellular Immunotherapy", Underscoring The Power Of CAR-iNKT As Next-Gen Solid Tumor Treatment

Benzinga·07/15/2025 12:25:00
Listen to the news

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today announced the publication of a peer-reviewed article titled "CAR-iNKT Cells: Redefining the Frontiers of Cellular Immunotherapy" in Frontiers in Immunology. The publication, authored by leading experts in iNKT biology, underscores the power of iNKT cells as the next-generation off-the-shelf platform for treating solid tumors—where conventional cell therapies have failed to deliver lasting results.